Investment Thesis
Pluri exhibits critical financial distress with negative stockholders' equity (-$18.6M), severe liquidity constraints (0.33x current ratio), and a cash runway of approximately one month given $15.8M annual cash burn against $3.4M in reserves. The company generates minimal revenue ($681K) while operating at massive losses, indicating pre-commercialization stage with insufficient capital to reach profitability.
Strengths
- Positive gross margin of 37.7% demonstrates some operational efficiency at unit level
- Biotech sector exposure offers potential for high-margin products upon successful commercialization
- Modest long-term debt of $1.3M limits leverage risk
Risks
- Negative stockholders' equity of -$18.6M indicates technical insolvency and balance sheet deterioration
- Critical liquidity crisis: current ratio of 0.33x with monthly cash burn exceeding available reserves
- Operating losses of $19.4M on $681K revenue shows no viable path to profitability without major capital infusion
- Revenue completely stagnant (0% YoY growth) with losses accelerating relative to top line
- Operating and net cash flows deeply negative, burning capital at unsustainable rate
Key Metrics to Watch
- Monthly cash burn rate and remaining runway
- Revenue growth and new product commercialization milestones
- Capital raise activities and dilution impact
- Path to operating cash flow breakeven
Financial Metrics
Revenue
681.0K
Net Income
-17.9M
EPS (Diluted)
$-1.90
Free Cash Flow
-15.8M
Total Assets
26.1M
Cash
3.4M
Profitability Ratios
Gross Margin
37.7%
Operating Margin
-2,847.6%
Net Margin
-2,634.5%
ROE
N/A
ROA
-68.9%
FCF Margin
-2,313.1%
Balance Sheet & Liquidity
Current Ratio
0.33x
Quick Ratio
0.33x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
-22.39x
Long-term Debt
1.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:17:45.510510 |
Data as of: 2026-03-31 |
Powered by Claude AI